BMY was as excited about interferon lambda for HBV as they were for HCV back in the day. That too was designed as more liver specific with fewer extrahepatic effects (and side effects). It never panned out obviously
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.